{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-025270","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-05-26T21:08:04+00:00","discovered_at":"2026-05-26T21:10:00.282009+00:00","generated_at":"2026-05-26T21:17:07.073628+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.75,"confidence":"low","headline":"Lipocine Presents Phase 3 Data for LPCN 1154 (Oral Brexanolone) for Postpartum Depression at ASCP","bullets":["May 26, 2026: Company highlighted results from placebo-controlled Phase 3 trial of LPCN 1154 for PPD at ASCP Annual Meeting.","The presentation and poster are furnished as exhibits but not included in the 8-K text; specific efficacy and safety endpoints are unconfirmed.","LPCN 1154 is an oral rapid-acting neuroactive steroid (brexanolone); this readout supports potential label expansion.","Stock impact uncertain without actual data; materiality depends on trial outcomes not disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025270","json":"https://secwatch.observer/filing/0001493152-26-025270.json","markdown":"https://secwatch.observer/filing/0001493152-26-025270.md","text":"https://secwatch.observer/filing/0001493152-26-025270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/0001493152-26-025270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:17:07.073628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}